Zivo Bioscience, Inc. · OTC:ZIVO

Zivo Bioscience — Corporate Update (April 2020)

27 slides from Zivo Bioscience's corporate update, April 2020

  1. Slide 1: The Post-Antibiotic Era and a New Focus on Immune Health

    The Post-Antibiotic Era and a New Focus on Immune Health An issues-oriented webinar for the conscientious investor April 2020 www.zivobioscience.com Hello and welcome to this series on life science investing. Today we explore the role of antibiotics in the 21st century and its effect on everything f

  2. Slide 2: Intro: ZIVO Bioscience, Inc. presenters

    intro ZIVO Bioscience, Inc. A new path to optimal health This webinar is presented by Dr. Amy Steffek and Bill Pfund, senior research & development principals at ZIVO Bioscience, Inc. a US-based biotech company 2

  3. Slide 3: Antibiotics – The good and the not so good

    Antibiotics – The good and the not so good Miracle drugs and their limitations 1928 1929 1943 1951 2006 Penicillin discovered Early Fermentation Large-scale WWII Production Approved as Growth Promoter FDA Bans Human Antibiotics Preventive Antibiotics Use Banned 2016 When penicillin and antibiotics i

  4. Slide 4: Drug pollution of water and irrigated farmlands

    Antibiotics – The good and the not so good Drug pollution of water and irrigated farmlands We can go further down this line of inquiry. There is no municipal sewage treatment plant in the world that can remove unmetabolized over-the-counter or prescription drugs from the water released back into the

  5. Slide 5: Deaths from Drug-Resistant Infections in 2050

    Antibiotics – The good and the not so good Deaths from Drug-Resistant Infections in 2050 Source: Review on Antimicrobial Resistance 2014 Antimicrobial resistant infections 10,000,000 Cancer 8,200,000 Diabetes 1,500,000 Diarrheal disease 1,400,000 Centers for Disease Control: Traffic accidents 1,200,

  6. Slide 6: Displacing Antibiotics: solutions and alternatives

    Displacing Antibiotics What are the solutions and alternatives? Chain of Infection Infectious Agent Treating Infectious Disease Susceptible Reservoirs Host Portal of Portal of Entry Exit Preventing Means of Transmission Infectious Disease Antibiotics will continue to have a place in medicine for the

  7. Slide 7: Displacing Antibiotics: treatment alternatives

    Displacing Antibiotics What are the solutions and alternatives? Chain of Infection Infectious Agent Treating Infectious Disease Susceptible Reservoirs Host C-Phage Lysins Engineered Antibodies Portal of Portal of Antimicrobial Peptides Exit Entry Plasma-Potentiated Small Molecular Entities Means of

  8. Slide 8: Displacing Antibiotics: prevention alternatives

    Displacing Antibiotics What are the solutions and alternatives? Chain of Infection Vaccines Infectious TLR Immune Modulation Agent LPS-Like Immune Stimulators Host Defense Peptides Susceptible Reservoirs Host Microbiome Enhancement Trace Metals Chelation Portal of Portal of Prebiotics Entry Exit Pre

  9. Slide 9: Displacing Antibiotics: poultry treatment progress

    Displacing Antibiotics What Progress is Being Made Poultry Treatment Options Ionophore Class Phytogenic Feed Additives TLR Immune Modulation What is the State of the Art? The poultry industry, where prophylactic use of antibiotics was once the norm, is a good example of where we currently stand in t

  10. Slide 10: Displacing Antibiotics: poultry prevention progress

    Displacing Antibiotics What Progress is Being Made Poultry Prevention Options Vaccines Phytogenic Feed Ingredients TLR Immune Modulation Microbiome Enhancement Eubiotics What is the State of the Art? From the prevention perspective, poultry vaccines are widely used, but they lack overall effectivene

  11. Slide 11: Market Intelligence: poultry market demand

    Market Intelligence Strong, Growing Demand Across the Globe Poultry Market Annualized Vaccines - $2.0B 6.2% CAGR Phytogenics - $800.0M 9.8% CAGR Eubiotics - $1.6B 8.3% CAGR Coccidiostats $1.5B 3.2% CAGR** **Primarily Ionophores The ability to grab market share with a truly effective antibiotic alter

  12. Slide 12: Market Intelligence: livestock antimicrobial drugs

    Market Intelligence Strong, Growing Demand Across the Globe Poultry Market Annualized Antimicrobial Drugs for Livestock 2018 US - Only Vaccines - $2.0B 6.2% CAGR Export** Phytogenics - $800.0M 9.8% CAGR Not independently reported (NIR) Tetracyclines $4.0 Billion Eubiotics - $1.6B 8.3% CAGR Sulfas Pe

  13. Slide 13: Market Intelligence: human market

    Market Intelligence Strong, Growing Demand Across the Globe Human Market Annualized World Population 1700 C.E. to 2050 C.E. Antibiotics $40.0B 12 Probiotics $56.6B 10 Autoimmune $110.0B 8 Antidiabetic $78.7B 6 4 2 0 1700 1750 1800 1850 1900 1950 2000 2050 The world’s human population is expected to

  14. Slide 14: Immune Health: The Way Forward

    Immune Health The Way Forward Our immune system holds the key to disease prevention and combating infectious pathogens. Understanding this complex ecology and enhancing its formidable capabilities is the future of medicine and the life sciences. Every day we’re exposed to pathogens of one form or an

  15. Slide 15: Immune Health: Innate immunity

    Immune Health Innate The Way Forward Basophil Our immune system holds Eosinophil the key to disease prevention and combating infectious pathogens. Activators Neutrophil Understanding this complex Macrophage ecology and enhancing its formidable capabilities is the Mast Cell future of medicine and the

  16. Slide 16: Immune Health: Innate and adaptive immunity

    Immune Health Innate Adaptive The Way Forward Basophil B Cell Our immune system holds T Cell Eosinophil the key to disease prevention and combating infectious pathogens. Activators Neutrophil Understanding this complex Macrophage ecology and enhancing its formidable capabilities is the Mast Cell fut

  17. Slide 17: A Dynamic Balancing Act

    Immune Health Innate Adaptive A Dynamic Balancing Act Basophil B Cell Innate and adaptive immunity T Cell Eosinophil work together to vanquish pathogens and provide healing relief to injured or Activators infected areas. Neutrophil Macrophage Mast Cell Dendritic Killer Cell Monocyte HOURS DAYS • Opt

  18. Slide 18: Cytokine Storm: When the System Goes Haywire

    Immune Health When the System Goes Haywire Clotting Cytokine Storm An overreactive immune response holds the potential for significant health risks and Lung even death. Injury Cell Death Immune Paralysis Renal Death Failure Shock • Sometimes immune cells become hyper‐reactive following an infection,

  19. Slide 19: Autoimmune Disorder: Attacking Healthy Cells

    Immune Health Arthritis Attacking Healthy Cells Multiple A faulty or unbalanced Sclerosis Autoimmune Disorder immune system can cause irreparable damage to tissues ALS and organs as the body attacks its own healthy cells. Type 1 Diabetes Hashimoto Lupus Thyroiditis IBD Graves Psoriasis Disease • Als

  20. Slide 20: Toll-Like Receptors

    Immune Health B Cell Toll-Like Receptors Detect bacteria, bacterial toxins, viruses, tissue fragments, necrosis Activate release of cytokines and chemokines Initiate Activator cells to trigger the adaptive immune system TLR receptors • Years of research have uncovered the closely-linked complexity a

  21. Slide 21: Toll-Like Receptor (TLR4)

    Immune Health Toll-Like Receptor 4 (TLR4) TLR4 Cell Membrane Interior of Immune Cell Coronavirus Cytokines • Of the ten toll-like receptors present in the human immune system, Toll-like receptor 4, in particular, is involved in many acute and chronic diseases, including cytokine storms and autoimmun

  22. Slide 22: Harnessing The Immune Response: Infectious Disease

    Market Intelligence Harnessing The Immune Response Infectious Disease Total NIH Disease Funding 2013-2020 7,000 Existing Products & New Research 6,000 Vaccine Adjuvants 5,000 NOD-like receptor agonists 4,000 Immune Modulators 3,000 Interferons Innate Defense Regulator (IDR) 2,000 Peptides 1,000 Micr

  23. Slide 23: Harnessing The Immune Response: Autoimmune Disorders

    Market Intelligence Harnessing The Immune Response Autoimmune Disorders & Disease Development Pipeline for Autoimmune Disorders Scleroderma Existing Products & New Research Multiple sclerosis Steroids Diabetes, type1 Non-Steroidal Anti-Inflammatory Lupus Drugs (NSAIDS) Interferons Psoriasis Immunosu

  24. Slide 24: Global Market Trends

    Market Intelligence Global Market Trends Market Size by Therapeutic in USD Human Microbiome Therapeutics by Application Vaccines $ 59.0B Others Immunomodulators $160.0B Oral health Microbiome Therapeutic $ 10.0M → $897.0M* Women's health Autoimmune Therapy $110.0B Immune health Rheumatoid Arthritis

  25. Slide 25: The Way Forward: Gut Health and Immune Health

    The Way Forward Gut Health Immune Health Convergence of Nutrition & Therapeutics Foods Non-Starch Polysaccharides Phosphorylated Lipids Vitamin A Bioavailable carotenoids Pharma Bioactive Fiber Prebiotics Lipid A Bioactives Probiotics Small Molecular Inhibitors Monoclonal Antibodies Innate Defense I

  26. Slide 26: About ZIVO Bioscience, Inc.

    The Presenting Company About ZIVO Bioscience, Inc. • US-based biotech company creating breakthroughs to fight disease and infection • Working to displace antibiotics and ionophores in the global food supply • Developing a new approach to rheumatoid arthritis, sepsis, lupus, ALS and other immune diso

  27. Slide 27: Thank You

    Thank You www.zivobioscience.com 27

ZIVO Bioscience — Corporate Update (April 2020) on 6ix